Keros Therapeutics Inc - ESG Rating & Company Profile powered by AI
This ESG rating covers 17 UN Sustainable Development Goals including: 'Gender Equality', 'Sustainable Cities & Communities' and 'Life below Water'. This report of Keros Therapeutics Inc is prepared by All Street Sevva using cutting edge Cognitive Robots. This page displays a free Environmental, Social and Governance report covering Keros Therapeutics Inc.
Keros Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 0.0 and governance score of 3.2.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | Keros Therapeutics Inc | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Keros Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Keros Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Keros Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Keros Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Keros Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Keros Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Keros Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Keros Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Keros Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Keros Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Keros Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Keros Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Keros Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Keros Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Keros Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Keros Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Keros Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Keros Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.